Company patents
UNIVERSITÉ DE MONTPELLIER
UNIVERSITÉ DE MONTPELLIER demonstrates a strong focus on pharmaceutical innovation, with Pharmaceutical Preparations comprising 41.3% of its portfolio and showing a significant 33.3% YoY growth in 2025, alongside Peptides & Proteins which surged by 125.0% in 2025, indicating an emerging focus despite a general slowdown so far in 2026 across most categories.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
75 US filings (since 2023) · 11 categories · 19 themes
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Systems that provide therapeutic stimulation or field therapy through wearable devices, often incorporating physiological sensing and closed-loop feedback for personalized and adaptive treatment.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Therapeutic application of electrical signals to nerves or tissues to modulate their activity, often using implantable devices, electrodes, and sophisticated programming for various conditions.
Design and application of devices that are inserted into the body or implanted to treat diseases, modulate physiological functions, or repair anatomical structures.
Methods and devices for integrating temperature sensors directly into materials, structures, or challenging environments (e.g., hydrogen tanks, concrete, ocean) to measure internal or localized temperatures.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Assays leveraging CRISPR-Cas systems (e.g., Cas12, Cas13) for highly specific and sensitive detection of target nucleic acids, often involving collateral cleavage activity or reporter molecules.
Methods and kits for amplifying nucleic acids at a constant temperature, enabling faster results and point-of-care applications, often used for pathogen or contamination detection.
Patents
Showing 1-10 of 121